Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral RIF + ATRA vs IV ATO + ATRA in Non-high-risk APL
NCT04175587Phase 3Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Dec 2019
- Primary completion
- Aug 2021
- Modality
- Small Molecules, Drug Delivery Systems
01
Overview
Phase 3, randomised, open-label trial of Compound Huangdai Tablet in acute promyelocytic leukemia (APL) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Event-free Survival at 2 years. Status: unknown.
02
Drugs
Compound Huangdai Tablet
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT04175587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04175587.